Table 2 Relationship (metaregression coefficient [95% CI]) of CAD prognostic factors with increasing quantiles of bilirubin

Age

0.174 [-1.148, 1.496]; p = 0.789

-0.488 [-2.832, 1.856]; p = 0.658

Females (%)

-2.450 [-11.350, 6.431]; p = 0.577

-8.164 [-14.531, -1.769]; p = 0.016

Body mass index

0.058 [-0.398, 0.519]; p = 0.797

-1.213 [-5.604, 3.178]; p = 0.444

Hypertension (%)

-0.966 [-8.020, 6.088]; p = 0.781

-1.261 [-10.397, 7.874]; p = 0.772

Dyslipidemia (%)

-1.682 [-8.649, 5.284]; p = 0.619

-2.629 [-25.826, 20.567]; p = 0.809

Diabetes mellitus (%)

-1.613 [-5.935, 2.707]; p = 0.451

1.637 [-11.572, 14.846]; p = 0.794

Smoking (%)

-1.421 [-6.014, 3.172]; p = 0.533

-0.709 [-7.872, 6.455]; p = 0.835

CVD history (%)

-1.210 [-5.969, 3.550]; p = 0.590

-0.290 [-4.775, 4.194]; p = 0.883

Total cholesterol

-1.582 [-17.828, 14.663]; p = 0.837

4.785 [-18.340, 27.909]; p = 0.640

Triglycerides

-5.881 [-25.141, 13.379]; p = 0.532

3–7.247 [-85.008, 70.513]; p = 0.827

High-density lipoprotein

1.550 [-2.562, 5.663]; p = 0.442

-0.711 [-23.041, 21.620]; p = 0.940

Low-density lipoprotein

0.991 [-6.170, 8.154]; p = 0.776

-0.809 [-3.912, 2.294]; p = 0.586

Hemoglobin

0.532 [0.103, 0.961]; p = 0.023

Serum creatinine

0.032 [-0.062, 0.126]; p = 0.472

0.012 [-0.050, 0.074]; p = 0.668

c-reactive protein

-0.014[-0.411, 0.385]; p = 0.939

0.676 [-0.844, 2.196]; p = 0.285

Alanine transaminase

0.740 [-0.959, 2.458]; p = 0.371

4.411 [-19.875, 28.698]; p = 0.60

Aspartate transaminase

0.737[-0.989, 2.463]; p = 0.384

27.278 [-21.803, 76.359]; p = 0.178

γ-glutamyltranspeptidase

3.204 [-4.485, 10.892]; p = 0.347

Alkaline phosphatase

3.433 [-1.669, 8.536]; p = 0.162

Statin use (%)

-6.804 [-20.256, 6.647]; p = 0.305

ACEi/ARB use (%)

-0.905 [-10.049, 8.239]; p = 0.832

Calcium channel blockers (%)

-2.829 [-17.783, 12.125]; p = 0.647

Beta blockers use (%)

-6.034 [-20.581, 8.512]; p = 0.394